



TEVA PHARMACEUTICAL INDUSTRIES LTD.

website: www.tevapharm.com


CONTACT INFORMATION:

Liraz Kalif
Investor Relations
Teva Pharmaceutical Industries Ltd.
 Tel ++972-3-926-7281
 Fax ++972-3-926-7519
 E-mail: liraz.kalif@teva.co.il

Kevin Mannix
Director, Investor Relations
Teva North America
 Tel (215) 591-8912
 Fax (215) 591-8803
 E-mail: kevin.mannix@tevausa.com


Net Sales

(U.S. \$ in millions)




Net Income⁽¹⁾

(U.S. \$ in millions)




Earnings per ADR⁽¹⁾⁽²⁾

(in U.S. \$)



Shareholders' Equity

(U.S. \$ in millions)



A COMPANY OVERVIEW

Teva Pharmaceutical Industries Ltd. Is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is one of the leading pharmaceutical companies in the world.

With over 100 years experience in the pharmaceutical industry, Teva enjoys a well-established international presence. Headquartered in Israel, close to 90% of Teva's sales, which totaled \$5.2 billion in 2005, are in North America and Europe.

In January 2006, the company closed its acquisition of IVAX Corporation, a U.S.-based generic provider of branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S., Central and Eastern Europe and Latin America among others.

With over \$7 billion in sales, operations in over 50 countries and approximately 26,000 employees worldwide, the newly combined company expands TEVA's leadership in global generics:

- Strengthens Teva's leading position in the U.S., the largest generic market in the world
- Expands Teva's leadership position in European generics – markets, which are poised for growth
- Transforms Teva's position in Latin America – through major expansion into new markets

The combined company offers the widest range of cost-effective pharmaceuticals, both generic and branded, to consumers, customers and healthcare providers. Teva is not simply an industry leader but the clear bellwether in its business.

Teva is the most actively traded share on the Tel-Aviv Exchange and among the most widely held Israeli shares on NASDAQ. Global institutional holdings are estimated to be two-thirds of Teva's shares, mostly by more than 600 U.S. institutions. Since November 2002, Teva's ADR is included in the NASDAQ-100 Index.


Market Data (as of May 7, 2006)

NASDAQ-100

Stock Symbol	TEVA
Recent Price	\$43.51
52 week range	\$29.50 - \$45.91
Market Capitalization	\$33 billion
# 14 in NASDAQ-100	

In-Market Global Sales of Copaxone®

(U.S. \$ in millions)



(1) Before non-recurring items (after tax).

(2) Reflects the 2:1 stock splits (Dec. 2002, June 2004) and potential dilution of contingent convertible Debt.



TEVA PHARMACEUTICAL INDUSTRIES LTD.



RECENT EVENTS

May 10, 2006 - Teva reported its First quarter 2006 financial results. Q1 sales amounted to \$1,672 million (up 28%). Net income and EPS, before non-recurring items (after tax), reached \$286 million (up 10%) and \$0.37 (down 3%) respectively.

May 1, 2006 - District court grants Teva summary judgment for Generic Zocor® exclusivity.

April 6, 2006 - Teva announces that higher dose of Copaxones showed increased efficacy in Multiple Sclerosis (MS); Doubling dose of Copaxone® further reduced relapses and lesions.

March 30, 2006 - Teva expands presence in China - increases it's equity stake in Hualida Biotechnology to 60%.

Sales by Region

(U.S. \$ in millions)

Q1 05: \$1,305 Million

- North America - 60%
- Europe* - 28%
- International - 12%



Q1 06: \$1,672 Million

- North America - 57%
- Europe* - 26%
- International - 17%



* Western Europe and Hungary

TEVA'S VISION

Teva is a global Israeli-based pharmaceutical company. Its vision is to become one of the world's leading pharmaceutical companies, by being the undisputed leader in the global generics industry and by developing a global franchise in selected innovative products originating from Israeli science.

Teva differentiates itself by balancing its portfolio with generic and innovative activities, by the strategic depth of its vertical integration, by combining local customer responsiveness with a "global edge" and by successfully managing increasing profitable growth and complexity.

Our success lies in the leadership of our management, the skills and devotion of our people, the quality of our offerings and our focus on customers and patients.

U.S. Pipeline* (as of May 8, 2006)

151 Filings

84 of these **151** are paragraph IV filings

151 Filings Over **\$92** Billion In Brand Sales

52 First-To-File:

Over **\$39** Billion In Brand Sales

* Including products under the agreement with Andrx and Impax

FDA Approvals February 2006 - May 2006

Product		Approval/ Launch Date	Branded Product		Indication
			Brand	market size (\$ millions)	
Polyethylene Glycol ⁽¹⁾	POS	04/05/06	Miralax®	\$153	Treatment of occasional constipation
Pravastatin Sodium ⁽²⁾	Tab	25/04/06	Pravachol®	\$1,500	Indicated for the treatment of certain hyperlipidemias and the primary prevention of coronary events.
Pantoprazole Sodium DR ⁽³⁾	Tab	21/04/06	Protonix®	\$2,400	Indicated for short term treatment of erosive esophagitis associated with GERD, maintenance of healing of erosive esophagitis and for treatment of hypersecretory conditions.
Mitoxantrone Hydrochloride ⁽¹⁾	Inj	12/04/06	Novantrone®	\$77	Indicated for use in combination with corticosteroids as initial therapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer, and in combination with other approved products for the initial therapy of acute nonlymphocytic leukemia in adults.
Deferoxamine Mesylate ⁽¹⁾	Inj	2/04/06	Desferal®	\$43	Indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias.
Topiramate ⁽³⁾	Tab	6/03/06	Topamax®	\$1,400	Anticonvulsant
Ondansetron ⁽³⁾	Inj	24/02/06	Zofran®	\$576	Indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and prevention of postoperative nausea and/or vomiting.

(1) Launched (2) Exclusivity (180 days) (3) Tentative approval